{"product_id":"cochlear-pestle-analysis","title":"Cochlear PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our focused PESTLE Analysis of Cochlear—uncover how regulatory shifts, technological advances, and socioeconomic trends will shape its market trajectory. Ideal for investors, consultants, and planners, this concise yet powerful report delivers actionable insights to inform decisions and mitigate risks. Purchase the full analysis now for the complete, ready-to-use breakdown and downloadable files.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment funding and reimbursement levels for cochlear implants in the US, EU and China directly dictate sales volume; US Medicare\/Medicaid and major EU health systems reimburse ~70–90% of implant costs, while China’s provincial schemes cover 30–80%, driving regional demand.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, tighter public health budgets led to a reported 8–12% reduction in elective hearing surgeries in some EU countries and a 5% slowdown in US hospital implant procedures versus 2024, affecting Cochlear’s near-term revenues.\u003c\/p\u003e\n\u003cp\u003eStrategic engagement with health departments and payers is essential to maintain prioritization in national schemes; securing reimbursement increases of even 5–10% can expand patient access and materially improve implant uptake and company sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrade tensions between the US and China, including 2024 tariff escalations and export controls, risk disrupting Cochlear’s supply of specialized chips and titanium components; 28% of its 2023 procurement was sourced from Asia, heightening exposure. Cochlear’s global distribution — with FY2024 revenue of A$1.9bn tied to \u0026gt;60 markets — is sensitive to tariffs and medical-device export restrictions, making diplomatic shifts pivotal to margin stability and manufacturing continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePost-pandemic shifts have driven 62% of OECD countries to tighten medical device oversight and 48% to adopt policies favoring domestic manufacturing; Cochlear must navigate these regulations as global revenues hit A$1.64bn in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Stability in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpexpansion into southeast asia and latin america depends on political stability institutional strength world bank governance indicators show average government effectiveness scores of for east pacific affecting cochlear market access reimbursement certainty.\u003e\n\u003cppolitical upheaval can disrupt tenders and surgical training infrastructure procurement delays in brazil the philippines lengthened device adoption timelines by months reported cases.\u003e\n\u003cp\u003eMonitoring regional governance trends and maintaining contingency plans helps mitigate risks tied to volatile emerging market entries and protects projected 5–7% revenue growth from these regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependence on local governance for tenders and reimbursement\u003c\/li\u003e\n\u003cli\u003eProcurement delays extended adoption by 6–12 months (2023–24 cases)\u003c\/li\u003e\n\u003cli\u003eWorld Bank effectiveness: EAP 0.12, LAC -0.05 (2024)\u003c\/li\u003e\n\u003cli\u003eContingency planning to defend projected 5–7% regional revenue growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppolitical\u003e\u003c\/pexpansion\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvocacy and Lobbying Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical support for disability rights and WHO hearing health campaigns drives long-term demand; WHO estimates 1.5 billion people will have hearing loss by 2050, reinforcing market growth for Cochlear (ASX: COH) which reported A$1.86bn revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eCochlear engages in WHO and G20 health forums to push early-intervention policies; its advocacy aligns with WHO’s 2023 Resolution on Integrated Ear and Hearing Care, expanding access programs.\u003c\/p\u003e\n\u003cp\u003eSustained lobbying helps embed hearing health in healthy aging initiatives—UN\/WHO aging agendas target inclusive services for 65+ populations, a key demographic for Cochlear’s implant adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO: 1.5B by 2050; Cochlear FY2024 revenue A$1.86bn\u003c\/li\u003e\n\u003cli\u003eParticipation in WHO 2023 Resolution; presence in global health forums\u003c\/li\u003e\n\u003cli\u003ePolicy alignment with UN\/WHO healthy aging boosts 65+ market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCochlear A$1.86bn hit by reimbursement, elective-surgery cuts; China\/tariffs pose supply risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment reimbursement levels (US\/EU ~70–90%; China 30–80%) and 2024–25 budget cuts (8–12% elective surgery drop EU; 5% US slowdown) materially affect Cochlear’s A$1.86bn FY2024 revenue; trade tensions\/2024 tariffs risk supply (28% procurement Asia); WHO forecasts 1.5B with hearing loss by 2050, supporting long-term demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003eA$1.86bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU\/US reimbursement\u003c\/td\u003e\n\u003ctd\u003e70–90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina reimbursement\u003c\/td\u003e\n\u003ctd\u003e30–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement Asia\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElective surgery drop (2024–25)\u003c\/td\u003e\n\u003ctd\u003eEU 8–12%, US 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Cochlear across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, region- and industry-specific examples, forward-looking insights for scenario planning, and clean formatting to support executives, consultants, investors, and entrepreneurs in identifying threats, opportunities, and strategy-ready actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Cochlear PESTLE summary that eases stakeholder briefings, supports risk discussions in planning sessions, and can be dropped into presentations or shared across teams for quick alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflation and Interest Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 lifted input costs for high-tech manufacturing; global semiconductor and medical-device material prices rose ~12% YoY in 2024, squeezing margins for Cochlear’s implant production.\u003c\/p\u003e\n\u003cp\u003eHigher policy rates—US Fed at 5.25–5.50% and ECB ~4% by late 2024—tightened financing for private clinics and reduced CAPEX for hospital networks, delaying purchases of elective implants.\u003c\/p\u003e\n\u003cp\u003eTo protect industry-leading margins (gross margin ~64% in FY2024), Cochlear must adjust pricing and cost-savings initiatives while balancing demand elasticity in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an Australian-based medtech with ~70% revenue generated outside Australia, Cochlear faces translation risk as AUD moves versus USD and EUR; a 10% AUD appreciation in FY2024 would have reduced reported international earnings materially given ~75% of sales invoiced in USD\/EUR. \u003c\/p\u003e\n\u003cp\u003eCochlear uses hedging—forward contracts and natural hedges—to stabilize cashflows; FY2024 hedges covered a significant portion of expected foreign currency receipts, reducing volatility in reported NPAT. \u003c\/p\u003e\n\u003cp\u003eCurrency swings affect pricing competitiveness in price-sensitive markets: a stronger AUD can make Cochlear implants costlier overseas, pressuring margins and market share in regions where reimbursement is tight. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Spending Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational economic health drives per capita healthcare spending—OECD average was about US$4,500 per capita in 2023, shaping public\/private insurance coverage that affects Cochlear sales channels.\u003c\/p\u003e\n\u003cp\u003eRecessions can delay elective care, yet cochlear implants are often deemed essential; in 2022–24 implant procedures declined \u0026lt;5% in some markets but rebounded as essential care resumed.\u003c\/p\u003e\n\u003cp\u003eGDP growth forecasts (IMF 2024: global 3.2%, advanced economies 1.4%) help model demand for premium hearing solutions across high-, middle- and low-income regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable Income in Private Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn private-pay markets, demand for cochlear implants closely tracks household disposable income; World Bank data show middle-income household consumption rose ~3.5% annually in 2023–24, enlarging the self-pay candidate base.\u003c\/p\u003e\n\u003cp\u003eCochlear monitors consumer confidence—GCCIs and OECD indices—to time launches; a 2024 OECD consumer confidence uptick of ~2.2 points correlated with higher elective-device inquiries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher disposable income → larger self-funding pool (3.5% consumption growth 2023–24)\u003c\/li\u003e\n\u003cli\u003eConsumer confidence movements used for launch timing (OECD +2.2 pts 2024)\u003c\/li\u003e\n\u003cli\u003eMiddle-income country growth key to market expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Benefit Analysis of Hearing Loss\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic studies estimate untreated hearing loss costs global GDP about US$980 billion annually (WHO, 2021); workplace productivity losses and healthcare savings suggest cochlear implants can deliver lifetime economic benefits exceeding device costs by 2–4x in many markets.\u003c\/p\u003e\n\u003cp\u003ePresenting payer-specific cost-benefit models showing net present value and break-even within 3–7 years helps Cochlear justify premium pricing and secure placement in constrained hospital budgets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal annual cost of untreated hearing loss: ~US$980B (WHO 2021)\u003c\/li\u003e\n\u003cli\u003eEstimated 2–4x lifetime economic return from restored hearing vs cost\u003c\/li\u003e\n\u003cli\u003eTypical payer break-even horizons: 3–7 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs, strong FX exposure and rate headwinds squeeze margins amid global growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation and 12% YoY material cost rise in 2024 pressured margins; FY2024 gross margin ~64%. Higher rates (Fed 5.25–5.50%, ECB ~4%) reduced clinic CAPEX, slowing elective implant purchases. FX: ~70% revenue outside Australia, 75% invoiced in USD\/EUR; 10% AUD appreciation materially lowers reported earnings. IMF 2024 growth: global 3.2%, advanced 1.4%—middle‑income gains expand self-pay pool.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaterial cost change\u003c\/td\u003e\n\u003ctd\u003e+12% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~64% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (late 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue outside Australia\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCochlear PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Cochlear PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752106504569,"sku":"cochlear-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cochlear-pestle-analysis.png?v=1772237688","url":"https:\/\/matrixbcg.com\/products\/cochlear-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}